Bibliographic Details
| Title: |
More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients |
| Authors: |
Candie Joly, Delphine Desjardins, Raphael Porcher, Hélène Péré, Thomas Bruneau, Qian Zhang, Paul Bastard, Aurélie Cobat, Léa Resmini, Olivia Lenoir, Laurent Savale, Camille Lécuroux, Céline Verstuyft, Anne-Marie Roque-Afonso, David Veyer, Gabriel Baron, Matthieu Resche-Rigon, Philippe Ravaud, Jean-Laurent Casanova, Roger Le Grand, Olivier Hermine, Pierre-Louis Tharaux, Xavier Mariette |
| Source: |
Frontiers in Immunology, Vol 14 (2023) |
| Publisher Information: |
Frontiers Media S.A., 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Immunologic diseases. Allergy |
| Subject Terms: |
COVID-19, pneumonia, SARS-CoV-2, type I interferon, prospective study, Immunologic diseases. Allergy, RC581-607 |
| More Details: |
BackgroundThe clinical outcome of COVID-19 pneumonia is highly variable. Few biological predictive factors have been identified. Genetic and immunological studies suggest that type 1 interferons (IFN) are essential to control SARS-CoV-2 infection.ObjectiveTo study the link between change in blood IFN-α2 level and plasma SARS-Cov2 viral load over time and subsequent death in patients with severe and critical COVID-19.MethodsOne hundred and forty patients from the CORIMUNO-19 cohort hospitalized with severe or critical COVID-19 pneumonia, all requiring oxygen or ventilation, were prospectively studied. Blood IFN-α2 was evaluated using the Single Molecule Array technology. Anti-IFN-α2 auto-Abs were determined with a reporter luciferase activity. Plasma SARS-Cov2 viral load was measured using droplet digital PCR targeting the Nucleocapsid gene of the SARS-CoV-2 positive-strand RNA genome.ResultsAlthough the percentage of plasmacytoid dendritic cells was low, the blood IFN-α2 level was higher in patients than in healthy controls and was correlated to SARS-CoV-2 plasma viral load at entry. Neutralizing anti-IFN-α2 auto-antibodies were detected in 5% of patients, associated with a lower baseline level of blood IFN-α2. A longitudinal analysis found that a more rapid decline of blood IFN-α2 was observed in fatal versus surviving patients: mortality HR=3.15 (95% CI 1.14–8.66) in rapid versus slow decliners. Likewise, a high level of plasma SARS-CoV-2 RNA was associated with death risk in patients with severe COVID-19.ConclusionThese findings could suggest an interest in evaluating type 1 IFN treatment in patients with severe COVID-19 and type 1 IFN decline, eventually combined with anti-inflammatory drugs.Clinical trial registrationhttps://clinicaltrials.gov, identifiers NCT04324073, NCT04331808, NCT04341584. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1664-3224 |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1250214/full; https://doaj.org/toc/1664-3224 |
| DOI: |
10.3389/fimmu.2023.1250214 |
| Access URL: |
https://doaj.org/article/30a8fd89add543c0a773bf38a3e5f405 |
| Accession Number: |
edsdoj.30a8fd89add543c0a773bf38a3e5f405 |
| Database: |
Directory of Open Access Journals |
